ResMed shares jump 8% on stellar start to FY25

This high-quality company continues to deliver the goods.

| More on:
A young man punches the air in delight as he reacts to great news on his mobile phone.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

ResMed Inc (ASX: RMD) shares have burst out of the gate on Friday morning.

At the time of writing, the sleep disorder treatment company's shares are up 8% to a new 52-week high of $38.46

Why are ResMed shares racing higher?

Investors have been scrambling to buy the company's shares this morning following the release of its first quarter update.

For the three months ended 30 September, ResMed reported an 11% increase in revenue to US$1,224.5 million. This was largely in line with consensus estimates for the period.

Management advised that this top line growth was driven by increased demand for its sleep devices and masks portfolio, as well as strong growth across its Residential Care Software business.

Revenue in the U.S., Canada, and Latin America, excluding Residential Care Software, grew by 11% for the period. Whereas revenue in Europe, Asia, and other markets, excluding Residential Care Software, grew by 10% in constant currency.

Finally, Residential Care Software revenue increased by 12% on a constant currency basis. This reflects continued organic growth in its portfolio.

Another big positive, which could be lifting ResMed shares today, is the massive improvement in its gross margin.

Management revealed that it improved 420 basis points to 58.6% mainly due to manufacturing efficiencies, component cost improvements, and an increase in average selling prices. Its non-GAAP gross margin increased by 320 basis points to 59.2% due to the same factors. The latter was a touch ahead of consensus estimates.

This ultimately led to ResMed's net income increasing 42% to US$311.4 million and diluted earnings per share increasing 42% to US$2.11 per share.

A quarterly cash dividend of US$0.53 per share (US$0.053 per share for its ASX-listed CDIs) was declared for the quarter.

Management commentary

ResMed's chair and CEO, Mick Farrell, was rightfully pleased with the company's performance during the quarter. He said:

Our first-quarter fiscal year 2025 results reflect ongoing momentum and strong execution across all areas of our business. We delivered 11% year-over-year revenue growth, and our focus on operational excellence resulted in another quarter of year-over-year margin expansion and a 34% increase in operating profit.

As we celebrate 35 years of growth and innovation, our recently launched 2030 strategy will further enable us to transform sleep health, breathing health, and healthcare technology at home. By building on our leadership in connected digital health, we are driving better care, simplifying the health journey, and improving access to our therapies globally so even more people worldwide are empowered to live healthier, higher-quality lives using products and services they love.

Another great quarter for ResMed, which continues to demonstrate that it can grow at a strong rate even after the emergence of weight loss wonder drugs like Ozempic.

ResMed shares are now up 80% from their 52-week low of $21.32.

Motley Fool contributor James Mickleboro has positions in ResMed. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended ResMed. The Motley Fool Australia has positions in and has recommended ResMed. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

woman testing substance in laboratory dish, csl share price
Healthcare Shares

Here's what could impact CSL shares from the biotech's AGM

The biotech giant's leadership had plenty to say.

Read more »

Man with a sleep apnoea mask on whilst sleeping.
Healthcare Shares

Why this fundie is backing ResMed shares in FY25

There's plenty more upside, this fund says.

Read more »

Senior woman with caregiver in the garden
Healthcare Shares

A 'golden era' is coming for these ASX healthcare shares

Here's why Blackwattle Partners sees tailwinds ahead for one particular category of healthcare shares.

Read more »

Two lab workers fist pump each other.
Healthcare Shares

Guess which ASX 200 healthcare stock is rising on big FDA news

Some big news is giving this stock a major lift on Thursday.

Read more »

A woman presenting company news to investors looks back at the camera and smiles.
Healthcare Shares

Why it's a big day for CSL shares today

This biotechnology company is holding its annual R&D event today.

Read more »

Lab worker puts hands in the air and dances around
Share Gainers

$6,000 invested in this ASX 200 stock 5 years ago is now worth $84,000!

ASX 200 investors who bought this growth stock five years ago have achieved remarkable gains.

Read more »

Doctor doing a telemedicine using laptop at a medical clinic
Healthcare Shares

Buy and hold this ASX dividend legend up 900% over 25 years

This stock has delivered healthy returns for shareholders.

Read more »

Two pharmacist talking to each other.
Healthcare Shares

Up 200% in a year, is the Chemist Warehouse merger already fully priced into Sigma shares?

Have investors gotten too ahead of themselves with Sigma?

Read more »